Medtronic settles states' probe into Infuse marketing for $12 million

BOSTON (Reuters) - Medtronic Plc has agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said on Wednesday.

Source: Reuters: Health - December 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news